Andrew has extensive experience collaborating with clients across a diverse spectrum of strategic engagements involving asset-, disease-, and therapeutic area-level growth strategy, as well as pipeline and portfolio prioritization and strategy. He has worked across all major therapeutic areas, with recent focus in immunology, neurology, hematology, and vaccines. Andrew is committed to working closely with client teams in highly collaborative partnerships to drive to customized and actionable solutions to their most pressing clinical and commercial questions.
Andrew has 12+ years of experience in the life sciences space. Prior to joining ClearView, he received his Ph.D. in Biomedical Engineering from Columbia University where his research focused on predicting the functional consequences of traumatic brain injury. While at Columbia, Andrew was a Fellow at Columbia Technology Ventures where he assessed the commercial potential of early-stage innovation within the life sciences. Andrew previously received an MS in Biomedical Engineering from Columbia University and a BS in Biochemistry from the University of Iowa.
Debbi Amanti Belanger
Seth Berman
Klaus Bredl
Steven Chao
Rishi Dalsania
Kim Goh
Ketan Kapadia
Philip Kenner
David McClain
Richard Mynahan
Kevin Richard
Mike Rizzo
Ryan Tubman
Sam Ulin
Debbie Zhuang
Sidnee Pinho
Kristine Hyde
Jim Caruso
Steve Rubman
Lainey Miller
Brian Gibbs
Jonathan Betts
Dean Griffiths
Jonathan Hodgson
Slater Hurst
Dave Konciak
Charles Mathews
Rohit Kumar
Mike Roy
Beko Binder
Jessica Berard
Peter Goldman
Maneesh Gujrati
Austin Hubbert
Jonny Juliano
Owen Im
Andrew Kang
Patrick Kuettner
Joanna Lee
Alexander Lehrman
Alec Marchuk
Matthew Murphy
Mike Murray
Soyeon Park
Olivia Piccione
Matthew Pfister
Kai-Ming Pu
Sarah Stapleton
Kelsey Yardumian